More About The Michelle Bradbury Lab Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Clinical Trials

First-in-Human Trial in Metastatic Melanoma Patients Using an FDA IND-Approved (IND#110375) Multimodal 124I-Labeled cRGDY Silica Nanomolecular Particle Tracer

Schematic of the 124I-cRGDY-PEGylated core-shell silica nanoparticle

We are evaluating a novel, tumor-selective silica nanoparticle tracer (124I-cyclic Arg-Gly-Asp-Tyr (cRGDY)-PEG-dots or 124I-cRGDY-PEG-dots) to determine whether this probe has desirable in vivo characteristics as a PET radiotracer, including efficient renal clearance, low background signal, stability, and biosafety, in humans. It is the first inorganic particle of its class to be approved as a “drug” for clinical use.  

Multicenter Trial Investigating Sodium Magnetic Resonance Imaging (MRI) for Monitoring Brain Tumor Response to Radiation

As part of a multicenter clinical trial with the University of Illinois at Chicago, we are using sodium MRI in high-grade glioma patients to serially monitor tissue viability, in the form of tissue sodium concentrations, during radiation therapy. A goal of the study is to evaluate whether sodium MRI is sensitive to tumor response on a time scale that could inform decision making about radiation therapy during treatment.

Image-Guided Stereotactic Biopsy of High-Grade Gliomas

We are investigating potential links between MRI-PET imaging findings at sites of regional heterogeneity within high-grade gliomas and correlative tissue markers and/or expression profiles derived from tissue biopsy specimens.